Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of DZD8586 in relapsed or refractory diffuse large B-cell lymphoma
CTR20240121Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Mar 2024; status: completed.
02
Drugs
birelentinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20240121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240121.